EP3689383
CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
Zusammenfassung
[0001] The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Anmelder
US HEALTH [US]
Erfinder
KOCHENDERFER JAMES NOBLE [US]
Externe Quellen
Klassifikation
IPC-Klassen
A61K 39/00A61K 48/00A61P 35/00A61P 35/02A61P 43/00C07K 14/005C07K 14/705C07K 14/725C07K 16/28C12N 15/62
CPC-Klassen
A61K 39/00A61K 39/395A61K 40/11A61K 40/31A61K 40/4215A61K 48/00A61P 35/00A61P 35/02A61P 43/00C07K 14/70503C07K 14/7051C07K 14/70517C07K 14/70521C07K 14/70578C07K 16/18C07K 16/2878C12N 15/62
AI: Life Sciences
warum
US Health CAR-T cell therapy — A61K39 + A61P35 + C07K + C12N. Pure biotech. Same as batch-1 (re-classification refresh).